Erratum: Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial (The Lancet (2017) 390(10089) (50–61) (S0140673617309790)(10.1016/S0140-6736(17)30979-0));Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

The Lancet

Volumn 390, Issue 10089, 2017, Pages 50-61

  Heier, Jeffrey S ^a   Kherani, Saleema ^b   Desai, Shilpa ^a   Dugel, Pravin ^c   Kaushal, Shalesh ^d   Cheng, Seng H ^e   Delacono, Cheryl ^e   Purvis, Annie ^e   Richards, Susan ^e   Le Halpere, Annaig ^e   Connelly, John ^e   Wadsworth, Samuel C ^e   Varona, Rafael ^e   Buggage, Ronald ^e   Scaria, Abraham ^e   Campochiaro, Peter A ^b  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c RETINAL CONSULTANTS OF ARIZONA   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ADENO ASSOCIATED VIRUS VECTOR SFLT01; AGENTS ACTING ON THE EYE; STEROID; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; SFLT01 FUSION PROTEIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; AQUEOUS HUMOR; ARTICLE; BEST CORRECTED VISUAL ACUITY; CATARACT; CHEMOSIS; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISCHARGE; EYE INFLAMMATION; EYE PAIN; FEMALE; FEVER; HUMAN; INTRAOCULAR PRESSURE; IRITIS; MALE; OCULAR PRURITUS; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA DISEASE; RETINA HEMORRHAGE; RETINA TEAR; SINGLE DRUG DOSE; SUBRETINAL FIBROSIS; SUBRETINAL FLUID; VERY ELDERLY; VISION; VISUAL IMPAIRMENT; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITRITIS; WET MACULAR DEGENERATION; ADMINISTRATION AND DOSAGE; BIOSYNTHESIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; GENE THERAPY; GENE VECTOR; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PARVOVIRINAE; PATHOPHYSIOLOGY; PROCEDURES; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PARVOVIRINAE; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 85020105309     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31456-3     Document Type: Erratum

References (29)

1. Rosenfeld, PJ, Brown, DM, Heier, JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006), 1419–1431.
2. Singer, MA, Awh, CC, Sadda, S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 119 (2012), 1175–1183.
3. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin, DF, Maguire, MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two year results. Ophthalmology 119 (2012), 1388–1398.
4. Honda, M, Sakamoto, T, Ishibashi, T, Inomata, H, Ueno, H, Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther 7 (2000), 978–985.
5. Gehlbach, P, Demetriades, AM, Yamamoto, S, et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Ther 10 (2003), 637–646.
6. Rota, R, Riccioni, T, Zaccarini, M, et al. Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6 (2004), 992–1002.
7. Bainbridge, J, Mistry, A, Alwis, MD, et al. Inhibition of retinal neovascularisation by gene transfer of soluble VEGF receptor sFlt-1. Gene Ther 9 (2002), 320–326.
8. Lai, CM, Shen, WY, Brankov, M, et al. Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys. Mol Ther 12 (2005), 659–668.
9. Daya, S, Berns, KI, Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21 (2008), 583–593.
10. Dinculescu, A, Glushakova, L, Min, SH, Hauswirth, WW, Adeno-associated virus-vectored gene therapy for retinal disease. Hum Gene Ther 16 (2005), 649–663.
11. Ivanova, E, Hwang, GS, Pan, ZH, Troilo, D, Evaluation of AAV-mediated expression of Chop-2-GFP in the marmoset retina. Invest Ophthalmol Vis Sci 51 (2010), 5288–5296.
12. Yin, L, Greenburg, K, Hunter, JJ, et al. Intravitreal injection of AAV2 transduces macaque inner retina. Invest Ophthalmol Vis Sci 52 (2011), 2775–2783.
13. Pechan, P, Rubin, H, Lukason, M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 16 (2009), 10–16.
14. Lukason, M, Dufresne, E, Rubin, H, et al. Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule. Mol Ther 19 (2011), 260–265.
15. Maclachlan, TK, Lukason, M, Collins, M, et al. Preclinical safety evaluation of AAV2-sFLT01—a gene therapy for age-related macular degeneration. Mol Ther 19 (2011), 326–334.
16. Early Treatment Diabetic Retinopathy Study research group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 103 (1985), 1796–1806.
17. Roquet, W, Roudot-Thoraval, F, Coscas, G, Soubrane, G, Clinical features of drusenoid pigment epithelial detchment in age related macular degeneration. Br J Ophthalmol 88 (2004), 638–642.
18. Cukras, C, Agrón, E, Klein, ML, et al. Natural history of drusenoid pigment epithelial detachment in age-related macular degeneration: Age-related eye disease study report No. 28. Ophthalmology 117 (2010), 489–499.
19. Caswell, AG, Kohen, D, Bird, AC, Retinal pigment epithelial detachments in the elderly: classification and outcome. Br J Ophthalmol 69 (1985), 397–403.
20. Rakoczy, EP, Lai, CM, Magno, AL, et al. Gene therapy with recombinant adeno-associated vectors for neovascular age-related macular degeneration: 1 year follow-up of a phase 1 randomised clinical trial. Lancet 386 (2015), 2395–2403.
21. Li, Q, Miller, R, Han, PY, et al. Intraocular route of administration defines humoral immune response and therapeutic potential. Mol Vis 14 (2008), 1760–1769.
22. Kotterman, MA, Yin, L, Strazzeri, JM, Flannery, JG, Merigan, WH, Schaffer, DV, Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Ther 22 (2015), 116–126.
23. Bennett, J, Ashtari, M, Wellman, J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Science Transl Med, 4, 2012, 120ra15.
24. Constable, IJ, Pierce, CM, Lai, CM, et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 14 (2016), 168–175.
25. Maguire, AM, Simonelli, F, Pierce, EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358 (2008), 2240–2248.
26. Bainbridge, JW, Smith, AJ, Barker, SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 358 (2008), 2231–2239.
27. Cideciyan, AV, Aleman, TS, Boye, SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinioid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 105 (2008), 15112–15117.
28. MacLaren, RE, Groppe, M, Barnard, AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 383 (2014), 1129–1137.
29. Campochiaro, PA, Nguyen, QD, Shah, SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 17 (2006), 167–176.